Analysis on the current situation of the most popu

2022-07-25
  • Detail

Analysis on the current situation of drug packaging materials in Western Europe

1. Large scale effect and three-dimensional development. Looking at the long-term drug R & D packaging material production enterprises in foreign countries, it is almost common that large-scale production is the rule. For example, schoot company of Germany produced about 2billion euros of glass products in 2003 (equivalent to about 15billion yuan). It has 91 branches and thousands of varieties all over the world, maintaining the world's advanced level in the production technology, equipment and product quality of medicinal glass tubes and ampoules. Industry influence, cross continental monopoly is obvious. The business contact is not a single point extension, but a linear expansion, with radiation managers. In the face of such competitors, China's pharmaceutical packaging material manufacturers should, according to the market demand, vigorously expand production capacity, develop new pharmaceutical packaging materials and containers, and strengthen international competitiveness

2. Subconsciousness of the concept of "full control"

in Western European countries, the government has not made mandatory provisions on the purification requirements of drug packaging material manufacturers. However, in view of the extensive contact between drug packaging materials and drugs, enterprises have turned the total quality control of drug product production into conscious action. Both the understanding of the quality assurance system and the standard implementation of SOP are in good detail

3. The ability of sustainable development

among the drug packaging material manufacturing enterprises investigated, there are family enterprises that have operated for hundreds of years, and groups controlled by the foundation. They all put the research on medicinal products that can meet the current and future needs and the gradual development of a series of key products in a prominent position. They are good at dynamically understanding the latest development trends of relevant products at home and abroad, inside and outside the industry, pay attention to the collection and evaluation of comprehensive information, and maximize the ability to pursue sustainable development

4. Seeking common ground while reserving differences and a pragmatic attitude

the consensus is that the drug packaging material manufacturers in Western Europe generally control the product quality according to the requirements of the European Pharmacopoeia. At the same time, enterprises generally have complete self inspection capabilities, and usually adopt batch inspection rather than sampling inspection to implement process management and terminal control for drug packaging products. However, the domestic drug packaging material manufacturers have insufficient investment in inspection equipment and imperfect inspection capacity, and the quality control of drug packaging material products needs to be improved

in addition, for controversial products, such as PVC infusion soft bags, Western European enterprises have adopted the method of restricting the use of drugs in combination with the use of drugs, that is, in the product manual or in the product performance introduction, they have clearly given the tips on which drugs can not be added to PVC infusion soft bags in clinical use. This has played an effective role in controlling edhp in PVC infusion soft bags and other factors affecting drug quality

5. Standardizing the market and making good use of the situation

the rubber stopper manufacturers in Western Europe have high labor intensity, and their production equipment may not be better than those of domestic drug packaging material manufacturers. There are thousands of rubber stopper formulas in China, and only 6 foreign main formulas are used to improve friction. However, the quality of the two products cannot be said the same, and there are serious hidden dangers in the quality of domestic rubber plugs. This is not a problem of technical content, but a result of quality awareness, low overall quality of employees and vicious competition. How to make good use of the situation to control product quality, the State Drug Administration has paid attention to this problem when formulating product quality standards for drug packaging materials. However, the key to solving the problem lies in that domestic production enterprises should strive to cultivate a good market environment, strengthen the awareness of product quality jc890 ⑵ 001 masonry mortar and plastering mortar for autoclaved aerated concrete, produce rubber plugs in the real sense, do not allow "kaolin" plugs to be mixed in pharmaceutical products, and practically achieve people-oriented and safety first

6. The refreshing International Packaging Exhibition

Germany Dusseldorf international packaging exhibition, with its large scale, the essence of exhibits, the novelty of products and the ingenious arrangement, gives people a momentum and a high-tech threat. The pharmaceutical packaging production machinery participating in the exhibition is impeccable in terms of modeling, processing technology and the progressiveness of mechatronics control. Among the exhibits, the ampoule laser sealing, the super large production tablet pressing machine, the bag making technology of non PVC infusion bags, the optical automatic detection, and the production lines of automatic filling, stoppering and pusher of injection needles all give people a refreshing feeling. Domestic drug packaging products should catch up with and surpass the world, and drug packaging production machinery should also catch up

Copyright © 2011 JIN SHI